Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.45 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | STK17B | O94768 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032904 | 0.85 | TSHR (0.38) | SMN1; SMN2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL7028412 | 0.82 | STING1 (0.47) | STING1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL7034684 | 0.78 | STING1 (0.57) | STING1 | |
| SCHEMBL7026274 | 0.75 | ALDH1A1 (0.40) | STING1ACHEALDH1A1HPGDKMT2A | |
| SCHEMBL7026271 | 0.74 | ALDH1A1 (0.45) | STING1ACHEALDH1A1HPGDKMT2A | |
| SCHEMBL7026280 | 0.72 | ALDH1A1 (0.43) | STING1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL7027417 | 0.72 | STING1 (0.50) | STING1ACHE | |
| SCHEMBL7029339 | 0.69 | STING1 (0.51) | STING1ACHE | |
| SCHEMBL7026421 | 0.69 | STING1 (0.47) | STING1 | |
| SCHEMBL7032737 | 0.69 | STING1 (0.47) | STING1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109570-A1 | Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases | MITSUI CHEMICALS, INC. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1284265-A1 | BENZOTHIOPHENE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109570-A1 | Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases | PPARG, PPARA, PPARD | STING1 878/4885ACHE 3734/4885STK17B 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.